Neurology Research International

Amyotrophic Lateral Sclerosis and Novel Therapeutic Strategies

Publishing date
24 Aug 2012
Submission deadline
06 Apr 2012

Lead Editor

1Neurobiology and developmental Sciences, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA

2Department of Neurology, Hannover Medical School, Hanover, Germany

3Department of Neurology, Johns Hopkins University, Baltimore, MD, USA

4Department of Pathology and Neuroscience, Toledo University, Toledo, OH, USA

5Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA

Amyotrophic Lateral Sclerosis and Novel Therapeutic Strategies


Amyotrophic lateral sclerosis (ALS) or motor neuron disease is a progressive, lethal, neurodegenerative disorder of motor neurons. The pathologic hallmark of this disease is the selective death of motor neurons in the brain and spinal cord, leading to paralysis of voluntary muscles. Studies on the disease-causing genes in cellular and animal models of ALS have led to a better understanding of the pathogenic mechanisms of motor neuron degeneration. Putative mechanisms include protein misfolding and aggregation, proteasome impairment, neuroinflammation, reactive oxygen species, excitotoxicity, and mitochondrial dysfunction. Transgenic mouse models of ALS and, more recently, induced pluripotent stem cells (iPS) provide an invaluable tool to test these putative mechanisms and novel therapeutics. Currently, there is only one approved treatment for ALS, and it is only modestly effective; therefore, there is a critical need for novel therapeutics to treat this devastating disease. We are interested in papers with relevance to the pathogenesis of ALS, with a particular focus on mechanisms related to genetic abnormalities in SOD1, TDP-43, FUS/LTS, and Valosin-containing protein (VCP/97). Papers addressing and critically evaluating recent preclinical and clinical trials in ALS would have priority. Potential topics include, but are not limited to:

  • Genetic discoveries in ALS
  • Newly developed models for ALS (rodents, nonrodents)
  • Mechanism of motor neuron degeneration
  • Role of inflammation in ALS
  • Contribution of glial cells to motor neuron death in ALS
  • Autophagy and ALS
  • Biomarkers for early diagnosis and clinical evaluation in ALS
  • iPS cells and ALS
  • ALS and FTD: distinct diseases or coincidental overlap
  • Experimental therapies in ALS
  • Current and future clinical trials in ALS patients

Before submission authors should carefully read over the journal's Author Guidelines, which are located at Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at according to the following timetable:

Neurology Research International
 Journal metrics
Acceptance rate19%
Submission to final decision58 days
Acceptance to publication25 days
Journal Citation Indicator0.330
Impact Factor-

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.